InvestorsHub Logo
Followers 30
Posts 4150
Boards Moderated 0
Alias Born 07/25/2007

Re: DewDiligence post# 1933

Tuesday, 02/09/2021 12:27:40 PM

Tuesday, February 09, 2021 12:27:40 PM

Post# of 3016
While RVS program is the closest to being an approved product, I am pleased about developments in the anti-HBV program. I am also pleased to hear that ENTA is getting closer to selecting anti-Covid-19 drugs, and that their approach is to attack the virus polymerase and virus protease rather than using an entry inhibitor. I know some expressed disappointment that the pace of development wasn't faster but ENTA has great expertise in antivirals and i is better to take a bit longer to generate a better drug. Both drugs are being designed to be orally administered and the idea is that someone beginning to show symptoms or testing positive would get a prescription and begin taking tablets that they can take everyday for a specified time frame. Still a long way to go but the approach sounds really smart.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News